nilutamide (Nilandron)

Also Known As:

Nilandron; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)- 2,4-imidazolidinedione; Anandron; RU 23908; RU 23908-10; RU-23908; 2,4-Imidazolidinedione, 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-

Networked: 119 relevant articles (15 outcomes, 20 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - Imidazolidines: 39
        nilutamide: 119

Experts

1.	Chen, Shen-Ming: 3 articles (01/2019 - 02/2017)
2.	Labrie, Fernand: 3 articles (10/2012 - 12/2004)
3.	Kokulnathan, Thangavelu: 2 articles (01/2019 - 01/2019)
4.	O'Brien, Peter: 2 articles (10/2014 - 03/2013)
5.	Arlen, Philip M: 2 articles (07/2008 - 03/2005)
6.	Gulley, James L: 2 articles (07/2008 - 03/2005)
7.	Ask, Kjetil: 2 articles (01/2006 - 11/2004)
8.	Camus, Philippe: 2 articles (01/2006 - 11/2004)
9.	Décologne, Nathalie: 2 articles (01/2006 - 11/2004)
10.	Holme, Jørn A: 2 articles (01/2006 - 11/2004)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 01/01/1991 - "Results of this study suggest that Anandron may be a safe and effective treatment for patients with advanced prostatic cancer." 12/01/1996 - "Nilutamide approved for metastatic prostate cancer." 01/01/1993 - "Median time to death from prostatic cancer was 30.0 months in the placebo group and 37 months in the nilutamide group. " 01/01/1991 - "Anandron: a new step in the treatment of advanced prostate cancer." 01/01/1991 - "Anandron: a new step in the treatment of advanced prostate cancer. "
2.	Disease Progression 01/01/2019 - "Nilutamide group showed improved response rate (RR=1.77, 95%CI 1.46-2.14, p<0.00001), disease progression (RR=0.59, 95%CI 0.47-0.73, p<0.00001), complete response (RR=2.13, 95%CI 1.40-3.23, p=0.003) and clinical benefit (RR=1.23, 95%CI 1.13-1.34, p<0.00001) when compared to placebo; however, stable disease favored the control group (RR=0.80, 95%CI 0.68-0.94, p=0.007). " 11/01/2000 - "Three randomized trials, SWOG-INT 0036, EORTC-30853 and the Anandron Study Group Trial, report a survival advantage and a longer time to disease progression with MAB, although only one reaches statistical significance. " 10/01/2005 - "All men received nilutamide 150 mg/day orally for > or = 8 weeks unless there was unacceptable toxicity or disease progression. " 01/01/1993 - "In castrated patients the addition of nilutamide improves objective response rates, bone pain, urinary symptoms, tumour markers and time to disease progression. " 04/01/1994 - "The combination of nilutamide and orchidectomy has a beneficial effect on pain of metastatic origin, levels of tumour markers, the objective response of disease and the time to disease progression. "
3.	Pain (Aches) 01/01/1995 - "Significant improvement or delayed deterioration in subjective parameters such as metastatic pain, performance status and urinary disorders strongly suggest (in the absence of validated questionnaires of quality of life at the time of this study) that orchiectomy plus nilutamide improves the quality of life as assessed by the subjective delay of progression, according to NPCP criteria, to an extent which outweighs the majority of adverse events." 01/01/1991 - "In three multicenter, randomized, double-blind placebo-controlled trials of castration and nilutamide involving 248 patients, the combination of nilutamide and castration decreased bone pain, improved performance status, and increased the number of patients with objective regression, compared with patients who were castrated but did not receive nilutamide. " 01/01/1993 - "In castrated patients the addition of nilutamide improves objective response rates, bone pain, urinary symptoms, tumour markers and time to disease progression. " 01/01/1991 - "In a short-term (29 days) comparison of nilutamide plus buserelin and buserelin plus placebo, nilutamide (300 mg/day), significantly reduced bone pain, and fewer patients experienced worsening pain than in the control group. " 04/01/1994 - "The combination of nilutamide and orchidectomy has a beneficial effect on pain of metastatic origin, levels of tumour markers, the objective response of disease and the time to disease progression. "
4.	Neoplasms (Cancer) 08/01/2002 - "When expressed as a percentage, the improvement in time to progression, overall and cancer specific survival in the Anandron treated patients was identical in both groups. " 02/01/2023 - "Cyclic voltammetry (CV) and differential pulse voltammetry (DPV) techniques have been used to examine the electrochemical performance of nilutamide (anti-cancer drug). " 01/01/1991 - "The administration of nilutamide to mice, castrated twenty-four hours before the inoculation of tumor cells, delayed the appearance of tumors and reduced their number. " 02/01/2017 - "Interestingly, the f-MWCNT was exhibited a superior electrocatalytic activity towards the anti-cancer drug nilutamide when compared with pristine MWCNT and unmodified electrodes. " 02/01/2017 - "A highly sensitive and selective electrochemical determination of non-steroidal prostate anti-cancer drug nilutamide based on f-MWCNT in tablet and human blood serum sample."
5.	Carcinoma (Carcinomatosis) 01/01/1991 - "Data are available on the pharmacokinetics and metabolism of nilutamide in the rat, dog, and human (normal volunteers and patients with advanced prostatic carcinoma). " 01/01/1988 - "Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate." 09/01/1990 - "A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma." 09/01/1990 - "These results suggest some benefit of the combined treatment (orchiectomy + nilutamide) over orchiectomy alone in the treatment of metastatic prostatic carcinoma." 01/12/2006 - "Nilutamide is a non-steroidal anti-androgen drug proposed in the treatment of metastatic prostatic carcinoma. "

Related Drugs and Biologics

1.	nilutamide (Nilandron)
2.	Androgens
3.	Androgen Antagonists (Antiandrogens)
4.	Flutamide (Eulexin)
5.	bicalutamide (Casodex)
6.	Gonadotropin-Releasing Hormone (GnRH)
7.	Androgen Receptors (Androgen Receptor)
8.	Buserelin (Suprefact)
9.	Dehydroepiandrosterone (DHEA)
10.	Hormones (Hormone)

Related Therapies and Procedures

1.	Orchiectomy (Orchidectomy)
2.	Castration
3.	Therapeutics
4.	Radiotherapy
5.	Life Support Care